Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/32922
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGörükmez, Özlem-
dc.contributor.authorGörükmez, Orhan-
dc.date.accessioned2023-06-05T12:12:50Z-
dc.date.available2023-06-05T12:12:50Z-
dc.date.issued2016-04-12-
dc.identifier.citationSağ, Ş. Ö. vd. (2016). "Spectrum of EGFR gene mutations and ALK rearrangements in lung cancer patients in Turkey". SpringerPlus, 5(1).en_US
dc.identifier.issn2193-1801-
dc.identifier.urihttps://doi.org/10.1186/s40064-016-2150-4-
dc.identifier.urihttps://springerplus.springeropen.com/articles/10.1186/s40064-016-2150-4-
dc.identifier.urihttp://hdl.handle.net/11452/32922-
dc.description.abstractThe EGFR gene and ALK rearrangements are two genetic drivers of non-small cell lung cancer (NSCLC). The frequency of EGFR mutations and ALK rearrangement varies according to not only ethnicity but also gender, smoking status and the histological type of NSCLC. In the present study, we demonstrated the distribution of EGFR mutations in 132 NSCLC patients by using a pyrosequencing technique and the distribution of ALK rearrangements in 51 NSCLC patients by using fluorescent in situ hybridization technique in Turkey. Additionally, we compared the clinicopathological data of NSCLC patients with the mutation status of EGFR in their cancerous tissues. Both EGFR mutations and ALK rearrangements were identified in 19 (14.39 %) and 1 (1.96 %) patients, respectively. We found EGFR mutations in codon 861, 719 and 858 with the ratios of 10.52 % (2/19), 10.52 % (2/19) and 31.58 % (6/19), respectively, and deletion of exon 19 in 47.37 % (9/19) of the patients. We found the frequency of EGFR mutations to be significantly higher in female patients and nonsmokers (p = 0.043, p = 0.027, respectively). Consequently, we found EGFR mutations to be more frequent in female patients and nonsmokers. Future studies on larger patient groups would provide more accurate data to exhibit the relationship between EGFR mutations and ALK rearrangements and the clinicopathological status.en_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAtıf Gayri Ticari Türetilemez 4.0 Uluslararasıtr_TR
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectScience & technology - other topicsen_US
dc.subjectLung canceren_US
dc.subjectNon-small cell lung canceren_US
dc.subjectEGFR mutationsen_US
dc.subjectALK rearrangementen_US
dc.subjectGrowth-factor-receptoren_US
dc.subjectAnaplastic lymphoma kinaseen_US
dc.subjectEML4-alk fusion geneen_US
dc.subjectClinicopathological featuresen_US
dc.subjectSomatic mutationsen_US
dc.subjectGefitiniben_US
dc.subjectAdenocarcinomaen_US
dc.subjectSensitivityen_US
dc.subjectPatternsen_US
dc.subjectSubtypeen_US
dc.titleSpectrum of EGFR gene mutations and ALK rearrangements in lung cancer patients in Turkeyen_US
dc.typeArticleen_US
dc.identifier.wos000375701400003tr_TR
dc.identifier.scopus2-s2.0-84964267768tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi//Tıbbi Genetik Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Dahiliye Anabilim Dalı/Tıbbi Onkoloji Bilim Dalı.tr_TR
dc.identifier.volume5tr_TR
dc.identifier.issue1tr_TR
dc.relation.journalSpringerPlusen_US
dc.contributor.buuauthorSağ, Şebnem Özemri-
dc.contributor.buuauthorTüre, Mehmet-
dc.contributor.buuauthorDeligönül, Adem-
dc.contributor.buuauthorŞahintürk, Serdar-
dc.contributor.buuauthorTopak, Ali-
dc.contributor.buuauthorGülten, Tuna-
dc.contributor.buuauthorKurt, Ender-
dc.contributor.buuauthorYakut, Tahsin-
dc.contributor.researcheridHNQ-2791-2023tr_TR
dc.contributor.researcheridAAH-8355-2021tr_TR
dc.identifier.pubmed27217997tr_TR
dc.subject.wosMultidisciplinary sciencesen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubMeden_US
dc.contributor.scopusid36638231300tr_TR
dc.contributor.scopusid6602186133tr_TR
dc.contributor.scopusid37088030300tr_TR
dc.contributor.scopusid57214054591tr_TR
dc.contributor.scopusid55313334700tr_TR
dc.contributor.scopusid6505944216tr_TR
dc.contributor.scopusid7006207332tr_TR
dc.contributor.scopusid6602802424tr_TR
dc.subject.scopusOsimertinib; Mutation; ErbB-1 Genesen_US
Appears in Collections:Scopus
Web of Science

Files in This Item:
File Description SizeFormat 
Sağ_vd._2016_PDF.pdf832.12 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons